How to Inject IGF-1 LR3: Sites, Syringes and Steps
Where to inject IGF-1 LR3, which syringe to use, how to read units and the hygiene steps that prevent infection.
Injection sites
Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.
- Belly: at least 2 inches (5 cm) away from the navel.
- Front and outer thighs.
- Back of the upper arms, if someone else can reach it.
- Rotate sites each time and avoid skin that is bruised, scarred or irritated.
Syringe and needle
U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for IGF-1 LR3 in studies: not reported in study abstracts (PubMed search, 11 Oct 2026).
How to read an insulin syringeStep by step
- 1Wash your handsUse soap and water, and work on a clean surface.
- 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
- 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
- 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
- 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
- 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
LR3 has no human injection data; the human paper is about an injection vial
The only human-related paper is a case report that identified His-tagged Long-R3-IGF-I, usually produced for biochemical studies, in an injection vial.[8]
Its authors say the effects in humans have not been described and that the product may be a by-product of biochemical studies rather than made for injection.[8]
Routes used in animals: pumps, infusions, nose drops
In diabetic rats, the IGF-I variants were infused via mini-osmotic pumps.[9]
In late-gestation fetal sheep, a 90-min IGF-1 LR3 infusion was tested for effects on glucose-stimulated insulin secretion.[10]
A mouse study tested intranasal LR3 treatment against cognitive decline and pathology in 5XFAD mice.[11]
In a rat study, half-lives for IGF-I, IGF-II, LR3-IGF-I and insulin were 872, 861, 563 and 324 min, respectively.[12]
A different molecule has a label: mecasermin (Increlex)
Increlex, the approved IGF-1 product, is administered by subcutaneous injection only, with a bar on intravenous use. That label does not apply to LR3.[13]
Its label ties administration to meals, because it has insulin-like hypoglycemic effects.[13]
Regulatory text for LR3 itself
Drugs@FDA returns no match for IGF-1 LR3.[14]
WADA's prohibited list covers IGF-1 and its analogues.[15]
Common questions
Where do you inject IGF-1 LR3?
No human injection protocol is cited here. The one human-related paper identified LR3 in an injection vial and notes that effects in humans are not described.[8]
What syringe is used for IGF-1 LR3?
Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.
How often is IGF-1 LR3 injected?
The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.
Is IGF-1 LR3 the same as Increlex?
No. Increlex is mecasermin, the approved IGF-1 product; Drugs@FDA returns no match for LR3.[13]
Does IGF-1 LR3 cause low blood sugar?
The approved IGF-1 label says its product has insulin-like hypoglycemic effects. No human data on LR3 are cited here.[13]
More on IGF-1 LR3
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: ("Long R3"[tiab] OR (LR3[tiab] AND (IGF[tiab] OR "IGF-1"[tiab] OR "IGF-I"[tiab] OR "insulin-like growth factor"[tiab]))) (109 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: ("Long R3 IGF-I"[tiab] OR "LR3 IGF-I"[tiab] OR "IGF-I LR3"[tiab] OR "LR3-IGF-I"[tiab] OR "IGF-1 LR3"[tiab] OR "LR3 IGF-1"[tiab] OR "[Long R3]IGF-I"[tiab]) AND (rat[tiab] OR rats[tiab] OR mice[tiab] OR infusion[tiab] OR muscle[tiab] OR pigs[tiab] OR in vivo[tiab]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: "long R3 IGF"[tiab] OR "long-R3 IGF"[tiab] OR "LR3-IGF"[tiab] OR "LR3 IGF"[tiab] OR "R3 IGF-I"[tiab] (95 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: ("LR3"[tiab] AND IGF[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab] OR clearance[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ("Long R3"[tiab] OR "IGF-1 LR3"[tiab] OR "LR3 IGF"[tiab] OR "LR3-IGF"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 8Detection of His-tagged Long-R³-IGF-I in a black market product.Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2010PMID 20675162Accessed 2 Oct 2026
- 9Insulin-like growth factor-I and more potent variants restore growth of diabetic rats without inducing all characteristic insulin effects.The Biochemical journal · 1993PMID 7683875Accessed 2 Oct 2026
- 10Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets.Journal of developmental origins of health and disease · 2023PMID 37114757Accessed 2 Oct 2026
- 11Intranasal long R3 insulin-like growth factor-1 treatment promotes amyloid plaque remodeling in cerebral cortex but fails to preserve cognitive function in male 5XFAD mice.Journal of Alzheimer's disease : JAD · 2025PMID 39610283Accessed 2 Oct 2026
- 12Clearance of IGFs and insulin from wounds: effect of IGF-binding protein interactions.The American journal of physiology · 1999PMID 10198302Accessed 2 Oct 2026
- 13INCRELEX prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 14Drugs@FDA (openFDA) search: active ingredient "IGF-1 LR3"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 15World Anti-Doping Code International Standard Prohibited List 2026 (in effect 1 January 2026)World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
Found an error? Report a correction.